Enfortumab Vedotin

An analysis of online conversations among health care professionals on social media in December revealed collective enthusiasm following approval of the first two gene therapies for treatment of sickle cell disease.

MADRID — Remarkable. Highly meaningful. Monumental.

The FDA approved enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer, according to an agency press release.

MADRID — A two-drug combination improved outcomes compared with first-line chemotherapy for adults with locally advanced or metastatic urothelial carcinoma, according to findings presented at ESMO Congress.

The combination of pembrolizumab plus enfortumab vedotin significantly extended OS and PFS as first-line treatment for adults with locally advanced or metastatic urothelial carcinoma, according to the manufacturers of both agents.

CHICAGO — First-line enfortumab vedotin-ejfv plus pembrolizumab conferred promising long-term outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma, study results presented at ASCO Annual Meeting showed.

The FDA granted accelerated approval to the combination of enfortumab vedotin-ejfv and pembrolizumab as first-line treatment for cisplatin-ineligible adults with locally advanced or metastatic urothelial carcinoma.

SAN FRANCISCO — Several potential genetic biomarkers may predict how patients with advanced urothelial carcinoma will respond to enfortumab vedotin, according to retrospective study results.

SAN FRANCISCO — Sacituzumab govitecan induced response among one-third of platinum-ineligible patients with metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy, according to study results.

The FDA announced several regulatory actions the past few weeks.